The development of COVID-19 treatment
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
Current and future status of JAK inhibitors
DP McLornan, JE Pope, J Gotlib, CN Harrison - The lancet, 2021 - thelancet.com
An enhanced understanding of the importance of Janus kinase (JAK) and signal transducer
and activator of transcription (STAT) signalling in multiple disease states has led to an …
and activator of transcription (STAT) signalling in multiple disease states has led to an …
Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the Writing Committee of the American Society for Apheresis: the …
A Padmanabhan, L Connelly‐Smith… - Journal of clinical …, 2019 - Wiley Online Library
ABSTRACT The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating and categorizing …
Special Issue Writing Committee is charged with reviewing, updating and categorizing …
Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway …
Background Inflammatory responses play a multiphase role in the pathogenesis of cerebral
ischemic stroke (IS). Ruxolitinib (Rux), a selective oral JAK 1/2 inhibitor, reduces …
ischemic stroke (IS). Ruxolitinib (Rux), a selective oral JAK 1/2 inhibitor, reduces …
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
DE Johnson, RA O'Keefe, JR Grandis - Nature reviews Clinical …, 2018 - nature.com
Abstract The IL-6/JAK/STAT3 pathway is aberrantly hyperactivated in many types of cancer,
and such hyperactivation is generally associated with a poor clinical prognosis. In the …
and such hyperactivation is generally associated with a poor clinical prognosis. In the …
Rusfertide, a hepcidin mimetic, for control of erythrocytosis in polycythemia vera
M Kremyanskaya, AT Kuykendall… - … England Journal of …, 2024 - Mass Medical Soc
Background Polycythemia vera is a chronic myeloproliferative neoplasm characterized by
erythrocytosis. Rusfertide, an injectable peptide mimetic of the master iron regulatory …
erythrocytosis. Rusfertide, an injectable peptide mimetic of the master iron regulatory …
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
This document updates the recommendations on the management of Philadelphia
chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by …
chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by …
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that
exceeds 35 years in young patients, but its natural history might be interrupted by …
exceeds 35 years in young patients, but its natural history might be interrupted by …
Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology
AT Gerds, J Gotlib, H Ali, P Bose, A Dunbar… - Journal of the National …, 2022 - jnccn.org
The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …
The emerging safety profile of JAK inhibitors in rheumatic disease
KL Winthrop - Nature Reviews Rheumatology, 2017 - nature.com
Tofacitinib is the first Janus kinase (JAK) inhibitor commercially approved for the treatment of
rheumatoid arthritis. This compound and a number of other JAK inhibitors are currently …
rheumatoid arthritis. This compound and a number of other JAK inhibitors are currently …